Structure of Apilimod
CAS No.: 541550-19-0
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Apilimod (STA 5326) acts as a potent IL-12/IL-23 inhibitor, strongly inhibiting IL-12 with IC50s of 1 nM and 2 nM in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively. It also serves as a potent and highly selective PIKfyve inhibitor.
Synonyms: STA 5326; LAM-002A free base; AIT-101
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 541550-19-0 |
Formula : | C23H26N6O2 |
M.W : | 418.49 |
SMILES Code : | CC1=CC(/C=N/NC2=NC(OCCC3=NC=CC=C3)=NC(N4CCOCC4)=C2)=CC=C1 |
Synonyms : |
STA 5326; LAM-002A free base; AIT-101
|
MDL No. : | MFCD09954108 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302 |
Precautionary Statements: | P280-P305+P351+P338 |
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
Dendritic cells (DC) | 50 nM | 4 hours | To investigate the effect of Apilimod on dendritic cell antigen presentation and T cell activation. Results showed that Apilimod-treated dendritic cells increased MHC-I and MHC-II expression and enhanced T cell activation. | PMC11213953 |
Primary murine cardiac fibroblasts | 100 nM | 48 hours | Apilimod almost completely abrogated collagen accumulation, reduced pro-fibrotic factors (collagen 1, collagen 3, Tgfβ) and inflaμMatory Il-6 transcript levels. | PMC8120213 |
HeLa cells | 100 nM | 16 hours | Apilimod significantly reduced the cell-surface binding of fluorescent TGFβ, indicating a reduction in the amount of surface available receptors in Apilimod-treated cells. | PMC8120213 |
RAW264.7 cells | 75 ng/mL | 3 days | To investigate the effects of IL-12 and IL-23 on the differentiation of RAW264.7 cells into osteoclasts. Results showed that IL-12 treatment alone reduced the number of TRAP+ osteoclasts, while IL-23 treatment alone promoted osteoclast formation and increased the average cell surface area. The combination of IL-12 and IL-23 also promoted cell proliferation and rescued the inhibitory effect of IL-12 on osteoclast formation. | PMC7295061 |
iPSC-MNs | 3 μM | Apilimod significantly improved the survival of ATP7AM1311V iMNs under neurotrophic withdrawal conditions | PMC9676097 | |
VeroE6 cells | 10 µM | 2 hours | To evaluate the inhibitory effect of Apilimod on SARS-CoV-2 replication, results showed that Apilimod effectively inhibited SARS-CoV-2 replication at nanomolar concentrations. | PMC9372968 |
A549/hACE2 cells | 50 nM | 2 hours | To evaluate the inhibitory effect of Apilimod on SARS-CoV-2 replication, results showed that Apilimod effectively inhibited SARS-CoV-2 replication at nanomolar concentrations. | PMC9372968 |
RM-1 cells | 10 nM | 24 hours | To evaluate the cytotoxicity of Apilimod on RM-1 cells, results showed that Apilimod alone had no significant cytotoxic effect on RM-1 cells | PMC11186457 |
MDCK cells | 3.8 to 24.6 µM | 3 days | To evaluate the inhibitory effect of Apilimod on various influenza strains, results showed that Apilimod effectively inhibited the cytopathic effect induced by influenza viruses | PMC10777833 |
Human nasal epithelium (ALI culture) | 0.2 mg/mL | 2 days | To evaluate the inhibitory effect of Apilimod on H1N1 virus in human nasal epithelium, results showed that Apilimod significantly reduced virus release | PMC10777833 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Mice | MC38 and B16F10 tumor models | Oral | 30 µg/kg | Three times per week for 30 days | To investigate the effect of Apilimod on tumor growth and immune response in vivo. Results showed that Apilimod significantly inhibited tumor growth and increased the proportion of intratumoral IFNγ+ CD8+ T cells. | PMC11213953 |
C57BL6/J mice | pressure overload-induced heart failure model | intraperitoneal | 2.5 mg/kg | Every 3 days for 42 days | Apilimod reduced myocardial interstitial fibrosis development and prevented left ventricular dysfunction. | PMC8120213 |
Mice | Calvarial defect model | Oral | Daily, for 10 weeks | To investigate the effect of Apilimod on calvarial defect repair. Results showed that Apilimod treatment significantly promoted bone formation and increased bone volume and semi-quantitative healing score. | PMC7086346 | |
Drosophila | Drosophila model expressing ATP7AM1311V | oral | 50 mg/kg | 24 and 4 hours before challenge, followed for 96 hours | Apilimod significantly improved the motor deficits in Drosophila expressing ATP7AM1311V | PMC9676097 |
BALB/c laboratory mice | COVID-19 mouse model | Intraperitoneal injection | 2 mg/kg | 5 times per week for several weeks | To evaluate the therapeutic effect of Apilimod in a COVID-19 mouse model, results showed that Apilimod was unable to mitigate disease-associated weight loss or reduce SARS-CoV-2 titers in lung tissues. | PMC9372968 |
C57BL/6J male mice | bone metastasis CRPC mouse model | tail vein injection | 100 mg/kg/day | Once daily for 4 weeks | To evaluate the inhibitory effect of Apilimod combined with LNP@PTEN on tumor growth and metastasis, results showed that the combination therapy significantly inhibited tumor growth and metastasis, and extended the survival of mice | PMC11186457 |
Mice | Experimental Autoimmune Uveoretinitis (EAU) | Oral | 100 mg/kg | daily for 14 days | Oral administration of STA-5326 significantly reduced the severity of EAU and decreased the number of IL-17-producing cells. | PMC2592812 |
BALB/c mice | H1N1 PR8 infection model | Intranasal administration | 5 mg/kg or 20 mg/kg | Once daily for 14 days | To evaluate the antiviral effect of Apilimod in H1N1-infected mice, results showed that Apilimod significantly reduced viral load and inflammation | PMC10777833 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02594384 | Lymphoma, Non-Hodgkin; Leukema... More >>i, Chronic Lymphocytic Less << | Phase 1 | Recruiting | December 2019 | United States, Alabama ... More >> Clearview Cancer Institute Recruiting Huntsville, Alabama, United States, 35805 Contact: Avitra Bone, RN 256-705-4283 studycoordinator@ccihsv.com Principal Investigator: Marshall Schreeder, MD United States, Florida Mayo Clinic Recruiting Jacksonville, Florida, United States, 32224 Contact: Lisa Melfi 904-953-3320 melfi.lisa@mayo.edu Principal Investigator: Taimur Sher, MD United States, Georgia Winship Cancer Institute at Emory University Recruiting Atlanta, Georgia, United States, 30322 Contact: Kaylan Dixon 404-778-4449 kaylan.dixon@emory.edu Principal Investigator: Jonathan Cohen, MD United States, Indiana Horizon Oncology Research, Inc. Recruiting Lafayette, Indiana, United States, 47905 Contact: Wael A Harb, MD 765-446-5111 wharb@horizonbioadvance.com Principal Investigator: Wael A Harb, MD United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Lauren Ramos 617-643-9607 lramos7@mgh.harvard.edu Principal Investigator: Jeremy Abramson, MD United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Corinne Parker 507-266-3784 parker.corinne@mayo.edu Principal Investigator: Stephen Ansell, MD United States, New York New York University School of Medicine Recruiting New York, New York, United States, 10016 Contact: Ion Marinescu 646-501-7920 Ion.Marinescu@nyumc.org Principal Investigator: Catherine Diefenbach, MD Weill Cornell Medical College Recruiting New York, New York, United States, 10021 Contact: Rita Gazivoda 212-746-0702 rig9021@med.cornell.edu Principal Investigator: Sarah Rutherford, MD United States, Texas University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Linda Claret 713-792-1044 lcclaret@mdanderson.org Principal Investigator: Loretta Nastoupil, MD United States, Virginia Virginia Cancer Specialists Recruiting Fairfax, Virginia, United States, 22031 Contact: VCS Phase 1 Team 703-208-3192 Karin.Choquette@usoncology.com Principal Investigator: Dipti Patel-Donnelly, MD United States, Washington Virginia Mason Medical Center Recruiting Seattle, Washington, United States, 98101 Contact: Anas Najjar 206-287-5671 Anas.Najjar@virginiamason.org Principal Investigator: David Aboulafia, MD Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.39mL 0.48mL 0.24mL |
11.95mL 2.39mL 1.19mL |
23.90mL 4.78mL 2.39mL |
Tags: Apilimod | STA 5326 | LAM-002A | AIT-101 | STA5326 | STA-5326 | AIT101 | AIT 101 | AIT-101 | IL-12 inhibitor | IL-23 inhibitor | PIKfyve inhibitor| FYVE domain-containing phosphatidylinositol 3-phosphate 5-kinase | Phosphatidylinositol 3-phosphate 5-kinase | 541550-19-0
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL